Navigation Links
Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel

COSTA MESA, Calif., March 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has added clinical trial sites in Israel for the planned Phase II dose escalation study of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. The Israeli sites are in addition to those previously planned for Switzerland.

"Israeli physicians are excited to be able to participate in this study, especially as it relates to TBI as a result of blast injury," said Chris J. Stern, company chairman and CEO. "Unfortunately, they have had to deal with blast victims for some time, both military and civilian. They see this as something that can help them improve outcomes for the victims they treat. They also have one of the best medical systems in the world and are especially skilled in treating TBI. So the data they collect should be absolutely first rate," said Stern.

Plans call for up to six treatment sites in Israel, the same number as in Switzerland. They will also use the same clinical protocol. All trials will be supervised by the Israeli affiliate of PFC Pharma Focus AG, a Swiss-based contract research organization. The company expects to begin the clinical trials in the second quarter.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. The forward-looking statements include those referring to plans for dose-escalation clinical trials in Switzerland and Israel, the expected time frame for the beginning of those trials, and hoped-for data from those trials. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the planned dose escalation studies in Switzerland and Israel will start in the expected time frame nor can there be any assurance that they will not be delayed by regulators there, or that those studies, when conducted, will be successful or provide data acceptable to the FDA. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Expands Board of Directors
2. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
3. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
4. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
5. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
(Date:11/24/2015)... Nov. 24, 2015  Twist Bioscience, a company ... Leproust, Ph.D., Twist Bioscience chief executive officer, will ... on December 1, 2015 at 3:10 p.m. Eastern ... City. --> --> ... Twist Bioscience is on Twitter. Sign up to ...
(Date:11/24/2015)... QC , Nov. 24, 2015 /CNW Telbec/ - ProMetic ... "Corporation") announced today that Mr. Pierre Laurin , President ... corporate presentation at the upcoming Piper Jaffray 27 th ... Palace Hotel, on December 1-2, 2015. st ... available for one-on-one meetings throughout the day. The presentation will ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
Breaking Biology News(10 mins):